Eyeworld

53 EW RETINA January 2015 Contact information Boyer: vitdoc@aol.com Das: tpdbei@gmail.com Hameed: zoya.hameed@nhs.net Hariprasad: retina@uchicago.edu Pielen: Pielen.Amelie@mh-hannover.de [month] 15 between the monthly and PRN arms." "The mean BCVA changes from baseline at M15 were +21.0 (PRN arm) and +18.7 (monthly arm) letters," they said. "At [month] 15, 70.7% and 66.3% of PRN- and monthly-treated patients gained ≥15 letters from baseline, respective- ly, and 76.8% and 71.3% of these patients achieved a Snellen equiva- lent of 20/40 or better, respectively. VA gains of +20.6 (BRVO) and +18.0 (CRVO) letters were highly clinically meaningful." "PRN treatment with [ranibi- zumab] in RVO (BRVO and CRVO patients), after reaching a stable disease state, provided VA gains comparable to monthly dosing over 15 months. Both the PRN and monthly groups demonstrated rapid and clinically meaningful reduc- tions in [central foveal thickness] on SD-OCT throughout the study," Dr. Hariprasad and co-authors said in the study abstract. "Safety was con- sistent with previous [ranibizumab] studies in RVO." Practical considerations An evidence-based analysis of these and other studies suggests that anti-VEGF therapy is becoming the standard of care for the treatment of macular edema related to retinal vein occlusion. The optimal dosing regimen is less clear. The VEGF load following a central vein occlusion is likely significantly greater than in diabetic macular edema or in age-related neovascularization, so a substantial loading period makes intuitive sense. The optimal dosing strategy has not yet been clarified, but several additional studies are underway to examine this important issue. EW Reference Hariprasad SM, Yau L, Sternberg G. Effect of Alternate Ranibizumab Dosing Regimens on Visual and Anatomic Outcomes in Patients with Retinal Vein Occlusion—The SHORE study. ARVO 2014. Abstract 3889. Poster C191. Editors' note: Dr. Boyer has financial interests with Alcon (Fort Worth, Texas), Allergan (Irvine, Calif.), Bayer (Leverkusen, Germany), Genentech, Novartis (Basel, Switzerland), and Regeneron. Dr. Hariprasad has financial interests with Genentech and Regeneron. Drs. Das, Hameed, and Pielen have no financial interests related to this article. K4-2018 right K4-2019 left Holland Holland DALK SCISSORS DALK SCISSORS K4-5075 These sharply curved scissors (right and left) feature miniature blades that closely match the radius of the previously dissected peripheral rim. The inner blade has a blunt, horizontally-oriented, spatulated tip which keeps the scissors in the proper plane, minimizing inadvertent perforation. The delicate, shortened, outer blade allows the surgeon to trim the tissue near the wall in a precise fashion. Designed by Edward Holland, MD Cincinnati, Ohio to safely excise stromal tissue This Vannas-style scissors has straight "micro blades" that are steeply angled to facilitate the dissection of stromal tissue out to the periphery. The distal tips of each blade are rounded and blunt to help protect underlying tissue while cutting. ® 973-989-1600 • 800-225-1195 • www.katena.com Watch it!

• Cover